A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)

NCT00209261 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Nocturnal Enuresis

Interventions

DRUG: MINIRIN Oral Lyophilisate
DRUG: Minirin tablet

Sponsor

Ferring Pharmaceuticals